• Palvella posted a Q2 net loss of $21.9 million, or $1.52 a share, widening from a $9.5 million loss a year earlier.
• R&D expenses more than doubled to $12.5 million, driven by manufacturing, angiokeratoma development, rolling NDA module costs, headcount, consulting.
• G&A costs more than doubled to $8.9 million, reflecting higher headcount and added public-company professional services.
• Cash, cash equivalents and short-term investments totaled $250.6 million at June 30, 2026.
• Submitted first rolling NDA module for QTORIN rapamycin in microcystic LMs; NDA completion targeted H2 2026, launch planned H1 2027 if approved.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palvella Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608040730PRIMZONEFULLFEED9803037) on August 04, 2026, and is solely responsible for the information contained therein.